Shanghai Securities News China Securities Network News (reporter Zhang Liang) Fu'an Pharmaceutical issued an announcement at noon on the 25th that the company's wholly-owned subsidiary Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. recently received a notice of approval for the drug supplement application approved by the State Drug Administration, and its product cefmetazole sodium for injection passed the consistency evaluation of the quality and efficacy of generic drugs.
According to the announcement, cefmetazole sodium for injection is suitable for the treatment of various infections caused by Staphylococcus aureus, Escherichia coli, Pneumonia bacillus, Proteus spp., Morganella Morris, Providence spp., Digestive Streptococcus, etc., which are sensitive to cefmetazole sodium, including sepsis, acute bronchitis, pneumonia, cholecystitis, peritonitis cystitis, lung abscess, etc.
Fu'an Pharmaceutical said that at present, there are 64 domestic production approvals for various specifications of cefmetazole sodium, with 27 manufacturers, and Qingyutang is the seventh enterprise to pass the drug consistency evaluation. Through the consistency evaluation, cefmetazole sodium for injection will further improve the quality of drugs and help improve the market competitiveness of its drugs.
![Fu'an Pharmaceutical: Aztreonam for injection passed the consistency evaluation of generic drug quality and efficacy[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)